A combined IgG and IgM antibody panel is available (refer to Chlamydia Antibody Panel, IgG & IgM by IFA (0065100)). Differentiate between Chlamydophila species (C. psittaci, C. pneumoniae). Differentiate early IgM response to infection from persistent low-level titer. Because of cross-reactivity, a C. pneumoniae-specific reaction will exhibit titers two-fold or greater than C. trachomatis or C. psittaci serology. Limited value in the diagnosis of most oculogenital (eg, eyes, genitalia) chlamydial infections.
Semi-Quantitative Indirect Fluorescent Antibody
New York DOH Approval Status
Plain red or serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as acute or convalescent.
Contaminated, hemolyzed, or hyperlipemic sera.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
< 1:20 C. trachomatis IgM.
< 1:20 C. pneumoniae IgM.
< 1:20 C. psittaci IgM.
The Chlamydia antibody test contains both species- and genus-specific antigens, and serological cross-reactions may be seen in both acute and convalescent samples (less than 1:128). A C. pneumoniae-specific reaction will exhibit titers twofold or greater than titers observed with C. trachomatis or C. psittaci serology. Ideally, acute and convalescent samples should be tested simultaneously at the same facility. If the sample submitted was collected during the acute-phase of illness, submit a marked convalescent sample within 25 days for paired testing. Seroconversion, a fourfold or greater rise in antibody titer between acute and convalescent sera, is considered strong evidence of recent infection.
The Chlamydia microimmunofluorescent assay utilizes C. psittaci, C. pneumoniae, and nine serotypes of C. trachomatis. It does not include the LGV strains of C. trachomatis.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Analyte Specific Reagent (ASR)
|Component Test Code*||Component Chart Name||LOINC|
|0065101||C. pneumoniae IgM Titer||6914-6|
|0065102||C. trachomatis IgM Titer||6920-3|
|0065103||C. psittaci IgM Titer||6917-9|
|0065131||Chlamydia IgM Panel Interpretation||59464-8|
- Chlamydia IgM Ab
- CT IgM Ab